To estimate whether magnesium therapy is the optimal management for women with mild preeclampsia.
RESULTS:
The base-case analysis showed that although the no-magnesium strategy results in a 15% reduction in neonatal mortality and avoids most maternal drug toxicity, it produces a twofold increase in maternal death and more neurologically compromised neonates compared with empiric magnesium. The two strategies are essentially equivalent with regard to aggregate maternal and neonatal outcomes (0.9792 compared with 0.9781 utilities). Multivariable sensitivity analysis using Monte Carlo simulation confirmed the decision to be a "toss-up," yielding a similar mean utility for no-magnesium and magnesium strategies (0.9789؎0.1374 compared with 0.9784؎0.1390, respectively).
CONCLUSION:
Our decision model indicates that either strategy, using or not using empiric magnesium sulfate therapy, is acceptable. The clinical decision of whether to use magnesium in patients with mild preeclampsia for seizure prophylaxis should be determined by the physician or institution, considering patient values or preferences and the unique risk-benefit trade-off of each strategy. (Obstet Gynecol 2007; 110:601-7) P reeclampsia affects 5-8% of all pregnancies in the United States. 1 Considering that approximately two thirds of the cases of preeclampsia are mild and that there are more than 4 million deliveries annually in the United States, 2 it is surprising that the optimal management of such a commonly encountered clinical syndrome remains in question.
Well-designed trials have established that magnesium sulfate is superior to placebo, 3 and to phenytoin, 4 for the prevention of eclamptic seizures in patients with severe preeclampsia. However, because magnesium therapy is not without risk and preeclampsia is thought to be a progressive disease in which morbidity is predominantly attributable to the severe forms, it is unclear whether magnesium sulfate should be used in all preeclamptic patients or just in patients with severe disease.
Despite two randomized controlled trials, 5, 6 it remains uncertain whether the benefits of magnesium therapy are worth the risks in patients with mild preeclampsia. The meaningful clinical outcomes, such as maternal death, neonatal death, and long-term neonatal compromise, as well as significant adverse effects of magnesium therapy such as cardiopulmonary events, occur so rarely that it would require a trial of impossible size to determine the answer. We developed a decision analytic model to make the risk-benefit trade-off of magnesium sulfate in mild preeclamptic patients explicit and to estimate which strategy, magnesium therapy or no magnesium therapy, is preferred for management of patients with mild preeclampsia.
MATERIALS AND METHODS
We used decision analysis to compare two management strategies, using or not using magnesium sulfate for seizure prophylaxis in patients with mild preeclampsia. The model was constructed to address the decision of empiric magnesium sulfate use in patients at the time of presentation for delivery, carrying a viable singleton fetus, with the diagnosis of mild preeclampsia at or beyond 34 weeks of gestation. The two strategies were compared based on the probability of clinical events and outcomes and the utility values of those events.
The basic assumption of the model was that the goal was to minimize the number of maternal deaths, neonatal deaths, and compromised neonates, weighed against minimizing the effect of toxicity associated with magnesium therapy. The clinical events and outcomes considered in the model were seizure, severe magnesium toxicity, placental abruption, neonatal neurologic compromise, neonatal death, and maternal death. We selected these events because they are the most clinically relevant to the disease state and seem to have the most effect on the overall clinical outcome. We assumed that the diagnosis of mild preeclampsia for women in the model was made using the criteria outlined by the Practice Bulletin from the American College of Obstetricians and Gynecologists, 1 meeting the criteria for the diagnosis of preeclampsia, but lacking criteria for the diagnosis of severe preeclampsia or eclampsia. Specifically, patients included in this analysis met the blood pressure (systolic blood pressures more than 140 but less than 160 mm Hg, and diastolic blood pressures more than 90 but less than 110 mm Hg) and proteinuria (more than ϩ1 on urinalysis or more than 300 mg in 24 hours, but less than ϩ3 or less than 5,000 mg in 24 hours) criteria for mild preeclampsia, and had no evidence of end-organ damage that indicates severe disease. We assumed that magnesium therapy would be administered by initial bolus, at a dose of 4 -6 g intravenously or 10 g intramuscularly, followed by a maintenance dose of 1-2 g/h intravenously or 5 g by intramuscular injection every 4 hours. We assumed that magnesium toxicity and placental abruption would be diagnosed clinically and that women who did not initially receive magnesium and went on to have a seizure would receive magnesium after the event to prevent additional seizures. Finally, we assumed that all additional clinical management for patients with mild preeclampsia, such as use of antihypertensive agents, would follow the recommendations outlined in the American College of Obstetricians and Gynecologists Practice Bulletin. 1 The decision model was developed and analyzed using TreeAge Pro 2006 (TreeAge Software, Cambridge, MA).
Each of the two theoretic clinical strategies for patients with mild preeclampsia, empirically using or not using magnesium sulfate, was considered and characterized as follows. A woman in the "magnesium" arm would receive magnesium sulfate therapy when mild preeclampsia was diagnosed. Women could experience one or more of the following clinical events: seizure, magnesium toxicity, or abruption. For the purposes of this model, magnesium toxicity was considered in its most severe form, defined as cardiopulmonary events (eg, pulmonary edema, congestive heart failure) and cardiac arrest. For each woman, the neonatal outcome could be a live neonate, a neurologically compromised neonate, or a neonatal death. Neonatal neurologic compromise was defined as severe deficit such as seizure or encephalopathy. Finally, each possible clinical scenario could result in maternal survival or a maternal death.
In the other arm, women with mild preeclampsia would not receive empiric magnesium (ie, "no magnesium"). As in the other strategy, the possibility of seizure or placental abruption was modeled. We assumed for the model that a woman who experiences a seizure would receive magnesium after the initial seizure to prevent further episodes of seizure. For these women, the possibility of magnesium toxicity was also modeled. As in the "magnesium" strategy, three neonatal outcomes were possible: a live neonate, a compromised neonate, or neonatal death. Each clinical scenario, just as in the opposing strategy, could culminate in maternal survival or maternal death.
Base-case probability point estimates and plausible confidence ranges for risks and outcomes were obtained from a quantitative review of the literature. Ranges were identified for use in sensitivity analyses to assess uncertainty in the model. We conducted a MEDLINE and PubMed literature search, using the key words, "mild preeclampsia," "magnesium," "magnesium and pregnancy," "preeclampsia," and "hypertension and pregnancy." We also searched the bibliographies of articles identified by the literature database searches. We restricted the literature search to studies involving humans and those published in English in the last 16 years. We excluded all unpublished studies, abstracts, case reports, meta-analysis, and review articles. Studies without control groups were only included for prevalence estimates of rare events in unique populations that could not be other-wise obtained in the literature. The remaining studies were reviewed and incorporated into the model if they included patients with mild preeclampsia, and contained information on the clinical events and outcomes considered.
Probability point estimates were calculated as weighted means of the probabilities in all included studies, based on study size. The probability ranges, for use in the sensitivity analyses, were defined as the extreme low and high values of the probability available in the literature. If only a single probability point estimate was available, a range was defined by the 95% confidence interval (CI), calculated using an exact 95% CI of binomial proportions.
The utility values and plausible ranges of uncertainty for long-term outcomes and short-term events were also derived from a quantitative literature review. The long-term outcome utilities were maternal death, neonatal death, and neonatal compromise. The point estimate for neonatal compromise utility was taken from the maternal perspective, and the range encompassed the utility value determined from the nurse's and obstetrician's perspective. Utility estimates were also obtained for two short-term events: magnesium toxicity and maternal seizure. Estimates for seizures and cardiopulmonary adverse events in nonpregnant patients were taken from the general medical literature because utilities for pregnant patients were not published. Then, these short-term disabilities were incorporated into the model as disutilities. 7 Each dis-utility was calculated as 1 minus the value of the utility, and then divided by 365 because a patient would experience a particular short-term utility as a single episode on a single day in a calendar year. Finally, we used the "decomposed" approach of combining utilities since multiple concomitantly occurring health states were modeled and would be difficult to rank with regard to overall value if a holistic approach had been used. 7 The two management approaches, using or not using magnesium therapy for patients with mild preeclampsia, were compared by utility value. The utility values were derived from the pathway probabilities (the product of all probabilities in a clinical pathway) and corresponding utility estimates for each outcome or event. As a secondary analysis, we used the model to analyze a hypothetical cohort of 160,000 patients to compare rates of cases of adverse events between the two strategies. This hypothetical cohort size was chosen to mimic the U.S. national population as a sample, with a rate of preeclampsia of approximately 6%, an annual delivery rate of approximately 4 million, and approximately two thirds of preeclamptic patients being nonsevere. We determined the number of major and minor clinical outcomes that would result from each clinical strategy in the hypothetical cohort. "Major" outcomes included maternal death, neonatal death, and neonatal compromise. "Minor" outcomes were defined as maternal seizure, placental abruption, and maternal magnesium toxicity. Other preeclampsia-related outcomes were not modeled because they were either extremely rare (eg, maternal stroke) precluding a meaningful analysis, had less clinical importance (eg, "blurry vision"), are less reliably reported (eg, hemorrhage), or were accounted for within the outcomes included (eg, drug-induced respiratory depression).
To address uncertainty regarding several of the baseline assumptions and probability estimates, multiple one-way sensitivity analyses were used to test the effect of varying the point estimate across the plausible range of each probability and utility. Two-way and three-way sensitivity analyses were also performed in the same manner, varying combinations of probability and utility ranges that seemed to have the most influence in the one-way sensitivity analyses. As a multivariable sensitivity analysis, Monte Carlo simulations were conducted. First, we used Monte Carlo simulation to perform a microsimulation using 160,000 trials to assess the variability in individual outcomes. Next, we used Monte Carlo simulation to complete probabilistic sensitivity analyses, assuming a normal distribution for each variable in one analysis and a triangular distribution for each variable in a second analysis. Because results of the various Monte Carlo analyses were similar, we report only the results for the microsimulation and the probabilistic sensitivity analysis in which we used a triangular distribution for the variables, because this distribution is more representative of the data.
RESULTS
Using the probability and utility estimates depicted in Table 1 , the base-case analysis showed that the "nomagnesium" strategy results in a 15% reduction in neonatal mortality but is essentially equivalent to the "magnesium therapy" strategy with regard to overall value, because the incremental gain in utility using the no-magnesium strategy is so small (0.9781 compared with 0.9792 utilities). Thus, the decision is a "toss-up." Considering the theoretical cohort of 160,000 patients with mild preeclampsia, the strategy of no magnesium use at onset of evaluation would prevent 416 neonatal deaths, but result in 240 more maternal deaths and 25 more neonates with neurologic compromise relative to the magnesium therapy strategy. Compared with the magnesium therapy strategy, a policy of no magnesium at the initiation of care would avoid 8,810 cases of major magnesium toxicity, but result in 2,018 more placental abruptions and 1,680 more maternal seizures (Table 2) .
One-way sensitivity analysis revealed that the model was sensitive to the probability of seizure, the probability of maternal death, and the probability of neonatal death. At rates of seizure more than 3.08%, a strategy of magnesium therapy would be preferred over the no-magnesium strategy (Fig. 1) . The sensitivity analysis of the probability of maternal death and the probability of neonatal death showed similar trends. For maternal death and neonatal death, a strategy of magnesium use would be preferred at the highest ranges of the probabilities (threshold values of 0.41% and 1.40% respectively). The model was robust to all of the utility estimates. Two-way and multiway sensitivity analysis confirmed one-way sensitivity analysis findings, and did not yield any additional variables to which the model was sensitive.
A Monte Carlo microsimulation of 160,000 iterations was performed. In this analysis, all model inputs were simultaneously, randomly varied within the ranges shown in Table 1 . The mean utility value generated by the Monte Carlo simulation for the no-magnesium strategy was slightly higher than the magnesium strategy, but the standard deviations around these means were wide relative to the small difference in the means (0.9789Ϯ0.1374 compared with 0.9784Ϯ0.1390, respectively). The simulation results indicate that in 96.3% of iterations, the model was indifferent between using magnesium or not when the threshold for indifference is set at a range equal to 2 standard deviations of error for the nomagnesium strategy utility. Figure 2 depicts the results of the Monte Carlo simulation, which indicate that the overwhelming decision is a "toss-up." Using Monte Carlo simulation to perform a probabilistic sensitivity analysis by defining variables as triangular distributions within their plausible range confirmed that the mean utilities for the "no-magnesium" and "magnesium" strategies were similar (0.9781Ϯ0.0019 compared with 0.9750Ϯ0.0026, respectively), with most model iterations falling in the range of indifference.
DISCUSSION
Despite a large body of literature on the use of magnesium sulfate for seizure prophylaxis in patients with severe preeclampsia, it has remained uncertain whether the potential benefits of magnesium therapy outweigh the risks in patients with mild preeclampsia. In our decision model assessing magnesium use in patients with mild preeclampsia, the base-case analysis showed the strategies to be essentially equivalent with regard to the overall value of aggregate maternal and neonatal outcomes. Likewise, the results and confidence intervals of the Monte Carlo analysis support the "toss-up" nature of the decision. In other words, the overall utility or value of each clinical strategy is so similar and the incremental difference in adverse events between strategies is so small that a single therapy cannot be identified as the superior choice.
Our conclusion that the strategies are equivalent with regard to overall clinical performance is based on two premises. The first is a distribution-based argument supported by the Monte Carlo analyses. Simply stated, the magnitude of effect or difference in mean utility values between strategies is relatively small compared with the variability in the estimates. 19 Second, prior research in health measurement suggests that the difference in utility values in our model is insignificant. Compared with patient-reported outcomes in clinical trials and estimates of minimally important differences in quality-of-life outcomes and health state utility measures, the difference in utility measures between our two modeled strategies is several-fold smaller. 19 -21 However, this decision model provides more than just a global assessment of the value or utility of each therapeutic strategy. The decision of whether to use magnesium in patients with mild preeclampsia is complex, requiring the balance of multiple competing but interrelated risks and benefits. Importantly, this model makes differences in risk for adverse outcomes and benefits gained in desired outcomes between strategies explicit. Because each therapeutic strategy has unique risks and benefits, the clinical decision between two strategies with similar overall utility must be based on preferences of patients and physicians, regarding strategy-specific risks and benefits.
The ability of this decision model to quantify risks and benefits and contrast them between strategies is most important for medical decision making, enabling the decision to be based not only on subjective preferences, but also on quantified risk-benefit tradeoffs. On a larger scale, if a policy of no empiric Fig. 1 . One-way sensitivity analysis on the probability of maternal seizure in patients with mild preeclampsia. The threshold value of probability of maternal seizure is 0.03081. magnesium therapy is adopted for a population of patients with mild preeclampsia, the strategy could result in a 15% reduction in neonatal death (or 400 fewer deaths per 160,000) and 98% reduction of severe magnesium toxicity (or 8,800 fewer toxic events per 160,000) at the expense of not gaining a 50% reduction in maternal death (or 240 more maternal deaths per 160,000) compared with a policy of empiric magnesium therapy.
The two randomized, controlled trials that assessed the use of magnesium sulfate therapy in patients with mild preeclampsia were not able to determine the optimal treatment strategy. Witlin et al 5 enrolled 135 patients, and Livingston et al 6 enrolled 222 patients. Both studies concluded that there was no difference in progression to severe disease or rates of magnesium toxicity between the placebo and the magnesium groups. But the 557 patients in both of these studies still leave them significantly underpowered to detect any differences in important maternal or perinatal outcomes between the groups. In a review article by Dr. Baha Sibai, 22 he pointed out that a trial for patients with mild preeclampsia, comparing magnesium to placebo, would require a very large sample. In fact, based on an eclampsia rate of 0.5% in patients with mild preeclampsia, a 50% reduction in seizure rate with magnesium therapy, an ␣ error of 0.05 and 80% power, each arm would require over 9,000 patients to prove a reduction in seizure rate in the treatment group. Our decision model results confirm that a randomized clinical trial of magnesium therapy for mild preeclampsia is unfeasible. For the outcomes that we examined in this analysis, using the same statistical assumptions and the incidence rates from the Magpie study, 3 a trial would require approximately 40,000 patients per group to detect a difference in maternal mortality.
Our decision analysis is not without limitations. Although our model is based on an exhaustive literature search, we were limited by the body of published literature on mild preeclampsia. The majority of this literature is observational and is subject to selection and information biases. However, for each probability or utility estimate, we used ranges in the sensitivity analysis commensurate with the amount of uncertainty expected for the level of evidence, accounting for uncertainty in the model. It is also important to note that a few of the probability estimates used in the model came from a single, large clinical trial due to a paucity of data in the literature. This trial enrolled patients with both mild and severe preeclampsia, but we were able to obtain event probabilities for our model from the subgroup with mild disease. Although the fact that some probability estimates came from this single source may be viewed as a methodologic limitation, we are confident that the data are reasonably accurate and generalizable, because they originate from a large, placebo-controlled, randomized study conducted in 33 countries and in that regard, represent the highest level of evidence. 3 We made two assumptions for the patients who seized. The first was that, had they not previously been receiving magnesium, it would be started to prevent further seizures. The second was that once a seizure occurred, the patient's diagnosis changed to eclampsia and the risks of subsequent clinical events were those of a patient with eclampsia. These assumptions are imperfect in that they do not consider the timing of the seizure with regard to delivery, and there is little information quantifying the benefits of magnesium therapy after an initial seizure in terms of maternal and neonatal terminal outcomes.
We also assumed that the probability of morbidity and mortality conferred by each clinical event was mutually exclusive, and therefore additive. For example, a patient who experienced an abruption as well as severe magnesium toxicity would have an increased risk of mortality both from the abruption and the magnesium toxicity. We made this assumption because the data from the literature seemed to support this, but it is possible that the morbidities associated with these events are not mutually exclusive or entirely independent, which would lead to an overestimate of event-specific morbidity in our model. Despite these weaknesses, some important conclusions can be drawn from our model of this commonly encountered clinical scenario. Generally, the absolute risks for maternal and neonatal morbidity and mortality are comparatively low in patients with mild preeclampsia. Considering both the low rate of adverse events, and the results of our model, which indicate that the two strategies produce aggregate outcomes with similar overall valuations, either using or not using empiric magnesium sulfate therapy is an acceptable strategy for patients with mild preeclampsia. This decision model does not unequivocally support a universal policy for using magnesium sulfate in patients with mild preeclampsia, since neither strategy is definitively superior. Ultimately, the clinical decision to use magnesium in patients with mild preeclampsia for seizure prophylaxis should be determined by the physician or institution, with consideration of patient values or subjective preferences regarding the risk-benefit trade-off specific to each clinical strategy.
